drugset / Trial / NCT00862121
A Study With Pentasa in Patients With Active Crohn's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesalamine | Small molecule | 6 g | Oral |